GeroScience

GLP-1 and GIP receptor activation does not directly cause muscle loss or block muscle cell formation in human muscle cells

Updated

Abstract

GIP receptor (GIPR) mRNA was consistently detected across all donors, while GLP-1 receptor (GLP-1R) mRNA was undetectable in skeletal muscle myoblasts from older adults with obesity.

  • Neither semaglutide nor GIP treatment altered atrophy-related gene expression or the secretome, with no significant protein changes observed.
  • Semaglutide reduced glycolytic and total ATP production rates and decreased lactate secretion, indicating a possible suppression of glycolytic activity.
  • Myotube thickness and differentiation were not impaired by either treatment, with GIP increasing myotube thickness after 8 days.
  • Direct stimulation of GLP-1 and GIP receptors did not produce major effects on atrophy, inflammation, morphology, myogenesis, or mitochondrial function in primary human skeletal muscle myotubes.
  • Findings suggest that the lean mass loss associated with incretin-based therapies may result from indirect mechanisms rather than direct pharmacological effects.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free